Skip to main content

GSK to acquire U.S.-based BELLUS Health for $14.75 per share

GSK said the deal will provide access to camlipixant, a treatment for refractory chronic cough currently in phase III development.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.